117527-50-1

Basic information

• Product Name: 2'-succinylpaclitaxel
• Synonyms: 2'-succinylpaclitaxel
• CAS NO: 117527-50-1
• Molecular Weight: 953.994
• Mol File: 117527-50-1.mol
• Article Data: 62

Chemical Properties

• Melting Point: >153oC (dec.)
• CAS DataBase Reference: 2'-succinylpaclitaxel(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-succinylpaclitaxel(117527-50-1)
• EPA Substance Registry System: 2'-succinylpaclitaxel(117527-50-1)

Safety Data

• Hazardous Substances Data: 117527-50-1(Hazardous Substances Data)

Usage

Description

2'-Succinylpaclitaxel is a semi-synthetic derivative of paclitaxel, a naturally occurring taxane diterpenoid compound originally isolated from the bark of the Pacific yew tree, Taxus brevifolia. It is characterized by the presence of a succinyl group at the 2' position of the molecule, which imparts unique properties and potential advantages over the parent compound, paclitaxel. This modification is aimed at enhancing the solubility, stability, and bioavailability of the drug, as well as potentially improving its therapeutic index.

Uses

Used in Pharmaceutical Industry:
2'-Succinylpaclitaxel is used as a chemotherapeutic agent for the treatment of various types of cancer. The expression is: 2'-Succinylpaclitaxel is used as an anticancer drug for its ability to target and disrupt the microtubule dynamics in cancer cells, thereby inhibiting cell division and inducing apoptosis.
Used in Drug Delivery Systems:
2'-Succinylpaclitaxel is used as a reactant for the preparation of molecular hydrogelators to be used as local delivery systems for chemotherapy. The expression is: 2'-Succinylpaclitaxel is used as a component in the development of hydrogel-based drug delivery systems for its potential to improve the targeted delivery and controlled release of the chemotherapeutic agent, enhancing the therapeutic efficacy and reducing systemic side effects.

Upstream product

• 110-15-6 succinic acid 
• 33069-62-4 taxol 
• 108-30-5 succinic acid anhydride 

Downstream Products

• 245110-80-9 paclitaxel-2’-succinyl-NHS 
• 1414915-82-4 C₇₈H₉₁N₁₁O₂₄ 
• 1414915-81-3 C₇₈H₉₁N₁₁O₂₄ 
• 1414915-80-2 C₇₈H₉₁N₁₁O₂₄ 
• 1414915-79-9 C₇₈H₉₁N₁₁O₂₄ 

Relevant articles and documents

Conjugation of Paclitaxel to Hybrid Peptide Carrier and Biological Evaluation in Jurkat and A549 Cancer Cell Lines

Paclitaxel (PTX) is one of the most potent cancer drugs; however, its low solubility and strong systemic side effects limit its clinical applications. To overcome these issues, new drug formulations and chemical modifications have been proposed. In this s

Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy

Purpose: Conjugation of nanocarriers with antibodies that bind to specific membrane receptors that are overexpressed in cancer cells enables targeted delivery. In the present study, we developed and synthesised two PAMAM dendrimer-trastuzumab conjugates t

Nitrogen-doped Carbon Nanodots for bioimaging and delivery of paclitaxel

Carbon nanodots (CNDs) hold great potential in imaging and drug delivery applications. In this study, nitrogen-doped CNDs (NCNDs) were coupled to the anticancer agent paclitaxel (PTX) through a labile ester bond. NCNDs showed excellent cell viability and

Conjugation of paclitaxel on adeno-associated virus (AAV) nanoparticles for co-delivery of genes and drugs

We have investigated the use of adeno-associated virus (AAV) nanoparticles as platforms for the co-delivery of genes and drugs to cancer cells. With its regular geometry, nanoscale dimensions, lack of pathogenicity, and high infection efficiency in a wide

Photoacoustic Imaging Quantifies Drug Release from Nanocarriers via Redox Chemistry of Dye-Labeled Cargo

We report a new approach to monitor drug release from nanocarriers via a paclitaxel–methylene blue conjugate (PTX-MB) with redox activity. This construct is in a photoacoustically silent reduced state inside poly(lactic-co-glycolic acid) (PLGA) nanopartic

Cancer nanomedicines stabilized by π-π stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations

Abstract Combination therapy using distinct mode-of-action drugs has sparked a rapidly growing interest because this paradigm holds promise for improving the therapeutic efficacy of anticancer therapy. However, the current drug combination therapy refers

Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy

Amphiphilic drug conjugates can self-assemble into nanovehicles for cancer drug delivery, but the key is to design stable yet intracellular labile drug linkers for drug retention during blood circulation but fast intracellular drug release. The conjugatio

Kinetic control over supramolecular hydrogelation and anticancer properties of taxol

We reported a kinetic control over supramolecular hydrogelation and more importantly over the anticancer properties of taxol.

Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy

Paclitaxel (PTX) is one of the most useful chemotherapeutic agents approved for several cancers, including ovarian, breast, pancreatic, and nonsmall cell lung cancer. However, it causes systemic side effects when administered parenterally. Photodynamic therapy (PDT) is a new strategy for treating local cancers using light and photosensitizer. Unfortunately, PDT is often followed by recurrence due to incomplete ablation of tumors. To overcome these problems, we prepared the far-red light-activatable prodrug of PTX by conjugating photosensitizer via singlet oxygen-cleavable aminoacrylate linker. Tubulin polymerization enhancement and cytotoxicity of prodrugs were dramatically reduced. However, once illuminated with far-red light, the prodrug effectively killed SKOV-3 ovarian cancer cells through the combined effects of PDT and locally released PTX. Ours is the first PTX prodrug that can be activated by singlet oxygen using tissue penetrable and clinically useful far-red light, which kills the cancer cells through the combined effects of PDT and site-specific PTX chemotherapy.

Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery

The hydrophobic block of polymeric micelles formed by amphiphilic copolymers has no direct therapeutical effect, and the metabolites of these hydrophobic segments might lead to some unexpected side effects. Here the hydrophobic core of polymeric micelles

Conjugation of paclitaxel to C-6 hexanediamine-modified hyaluronic acid for targeted drug delivery to enhance antitumor efficacy

Polymer-based paclitaxel (PTX) conjugates have demonstrated application potentials to improve the water solubility and enhance the efficiency of drug delivery. In this study, a novel HA-based drug conjugate, HA-6-PTX, was designed and successfully synthes

Stepwise orthogonal click chemistry toward fabrication of paclitaxel/galactose functionalized fluorescent nanoparticles for hepg2 cell targeting and delivery

In this report, we used stepwise orthogonal click chemistry (SOCC) involving strain-promoted azide-alkyne cycloaddition (SPAAC) and microwave-assisted Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) to assemble an anticancer drug (paclitaxel, PTX) and

Synthesis and evaluation of water-soluble poly(vinyl alcohol)-paclitaxel conjugate as a macromolecular prodrug

Paclitaxel (PTX) is an antitumor agent for the treatment of various human cancers. Cremophor EL and ethanol are used to formulate PTX in commercial injection solutions, because of its poor solubility in water. However, these agents cause severe allergic r

Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates

Paclitaxel (1a), a well known antitumor agent adopted mainly for the treatment of breast and ovarian cancer, suffers from significant disadvantages such as low solubility, certain toxicity and specific drug-resistance of some tumor cells. To overcome thes

Self-assembled nanoparticles from hyaluronic acid-paclitaxel prodrugs for direct cytosolic delivery and enhanced antitumor activity

A prodrug-based nanosystem obtained by formulating prodrug and nanotechnology into a system is one of the most promising strategies to enhance drug delivery for disease treatment. Herein, we report a new nanosystem based on HA-PTX conjugates (HA-PTX Ns),

Fluorescence opening type diarylethene fluorescent probe, and preparation method and application thereof

The invention provides a fluorescence opening type diarylethene fluorescent probe, and a preparation method and application thereof. The fluorescence opening type diarylethene fluorescent probe has a structure as shown in a formula I, the probe is compose

Reduction-Sensitive Dextran-Paclitaxel Polymer-Drug Conjugate: Synthesis, Self-Assembly into Nanoparticles, and in Vitro Anticancer Efficacy

Delivery systems that can encapsulate a precise amount of drug and offer a spatiotemporally controlled drug release are being actively sought for safe yet effective cancer therapy. Compared to polymer nanoparticle (NP)-based delivery systems that rely on